These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1965934)

  • 1. Classification and tissue selectivity of calcium antagonists.
    Nayler WG
    Z Kardiol; 1990; 79 Suppl 3():107-11. PubMed ID: 1965934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of calcium antagonists on myocardial and smooth muscle membranes.
    Zakhari S
    Drugs Exp Clin Res; 1986; 12(9-10):817-29. PubMed ID: 3539569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental pharmacology of calcium antagonists].
    Godfraind T
    Therapie; 1993; 48 Spec No():637-49. PubMed ID: 8091349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The voltage-dependent non-selective cation channel sensitive to the L-type calcium channel blocker efonidipine regulates Ca2+ influx in brain vascular smooth muscle cells.
    Matsuoka T; Nishizaki T; Nomura T
    Biochem Biophys Res Commun; 1997 Nov; 240(2):484-7. PubMed ID: 9388505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium antagonism in vascular smooth muscle cells.
    Fleckenstein-Grün G
    Pflugers Arch; 1996; 432(3 Suppl):R53-60. PubMed ID: 8994543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium antagonists. Great tissue selectivity is the basis of their therapeutic use].
    Högestätt ED; Andersson KE
    Lakartidningen; 1997 Sep; 94(36):3024-6, 3029-31. PubMed ID: 9312623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular T-type calcium channels: physiological and pharmacological significance.
    Triggle DJ
    J Hypertens Suppl; 1997 Dec; 15(5):S9-15. PubMed ID: 9481611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors modifying the tissue selectivity of calcium-antagonists.
    Spedding M; Fraser S; Clarke B; Patmore L
    J Neural Transm Suppl; 1990; 31():5-16. PubMed ID: 1963634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tissue selectivity of calcium channel blockers].
    Godfraind T
    C R Seances Soc Biol Fil; 1998; 192(1):121-35. PubMed ID: 9759358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium antagonists--terminology, classification and comparison.
    van Zwieten PA
    Arzneimittelforschung; 1985; 35(1A):298-301. PubMed ID: 4039169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
    Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
    J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.
    Hu H; Marban E
    Mol Pharmacol; 1998 May; 53(5):902-7. PubMed ID: 9584217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent development in calcium channel antagonists.
    Triggle DJ; Janis RA
    Magnesium; 1989; 8(5-6):213-22. PubMed ID: 2559260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].
    Takahara A
    Clin Calcium; 2010 Jan; 20(1):24-30. PubMed ID: 20048430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological modulation of calcium and potassium channels in isolated vascular smooth muscle cells.
    Klöckner U; Trieschmann U; Isenberg G
    Arzneimittelforschung; 1989 Jan; 39(1A):120-6. PubMed ID: 2541731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium channels in smooth muscle.
    Karaki H; Weiss GB
    Gastroenterology; 1984 Oct; 87(4):960-70. PubMed ID: 6088352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tetrandrine on free intracellular calcium in cultured calf basilar artery smooth muscle cells.
    Wang B; Xiao JG
    Acta Pharmacol Sin; 2002 Dec; 23(12):1121-6. PubMed ID: 12466050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological basis of Ca2+ channels and Ca2+ channel antagonists].
    Adachi-Akahane S
    Clin Calcium; 2005 Oct; 15(10):1589-97. PubMed ID: 16199903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.